Gobeil Marc-Antoine, Guillemette Albert, Silhadi Meziane, Charbonneau Laurence, Bergeron David, Dominguez-Vargas Adan-Ulises, Dancause Numa, Jodoin Nicolas, Assi Elie Bou, Amzica Florin, Obaid Sami, Fournier-Gosselin Marie-Pierre
Department of Medicine, University of Montreal, Montreal, Quebec, Canada.
Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada.
Eur J Neurosci. 2025 Mar;61(5):e70046. doi: 10.1111/ejn.70046.
Non-motor symptoms can severely affect the quality of life of Parkinson's disease-afflicted patients, with the most common ones being pain, sleep impairments, and neuropsychiatric manifestations. In advanced cases, complex fluctuations of motor and non-motor symptoms can occur despite optimal medication. Research on deep brain stimulation of the subthalamic nucleus suggests that it may provide benefits for treating non-motor symptoms in addition to improving motor symptoms. With recent advancements in deep brain stimulation technology, simultaneous recording of local field potentials and delivery of therapeutic stimulation is possible. This opens new possibilities for better understanding the pathophysiology of non-motor symptoms in Parkinson's disease and for identifying potential electrophysiological biomarkers that accurately represent these symptoms. Specifically, this review aims to highlight potential local field potential biomarkers of non-motor symptoms in the subthalamic nucleus. The main findings indicate that activities in the beta frequency band are associated with nociception and sleep impairments such as insomnia and rapid eye movement sleep behavior disorders. Additionally, activities in the theta and alpha frequency bands seem to reflect neurocognitive manifestations, including depression and impulse control disorders. A better understanding of these biomarkers could improve the clinical management of non-motor symptoms in Parkinson's disease. They hold promise for adjusting deep brain stimulation parameters in open-loop settings and might eventually be applied in closed-loop deep brain stimulation systems, though their true impact remains uncertain.
非运动症状会严重影响帕金森病患者的生活质量,其中最常见的症状包括疼痛、睡眠障碍和神经精神表现。在疾病晚期,尽管进行了最佳药物治疗,运动和非运动症状仍可能出现复杂波动。对丘脑底核进行深部脑刺激的研究表明,除了改善运动症状外,它可能对治疗非运动症状也有益处。随着深部脑刺激技术的最新进展,同时记录局部场电位和进行治疗性刺激成为可能。这为更好地理解帕金森病非运动症状的病理生理学以及识别准确反映这些症状的潜在电生理生物标志物开辟了新的可能性。具体而言,本综述旨在突出丘脑底核中非运动症状的潜在局部场电位生物标志物。主要研究结果表明,β频段的活动与伤害感受以及失眠和快速眼动睡眠行为障碍等睡眠障碍有关。此外,θ和α频段的活动似乎反映了神经认知表现,包括抑郁和冲动控制障碍。更好地理解这些生物标志物可以改善帕金森病非运动症状的临床管理。它们有望在开环设置中调整深部脑刺激参数,并且最终可能应用于闭环深部脑刺激系统,尽管它们的实际影响仍不确定。